Click here for slides on this topic


Postprandial

Occurring after a meal.


The following content matched the glossary term: Postprandial

ADA 2016 Glycemic Targets

Top

Glycemic targets and A1C for adults with diabetes from the 2016 ADA guidelines

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults

Top

Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once weekly glucagon like peptide 1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012;46(1):68-78. OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM).

Influence of preprandial vs postprandial insulin glulisine on weight and glycaemic control in patients initating basal-bolus regimen for type 2 diabetes

Top

Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M. Influence of preprandial vs postprandial insulin glulisine on weight and glycaemic control in patients initating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parlallel, open-label study. Diabetes Obes Metab. 2011;13(12):1142-1148. Insulin therapy is commonly associated with weight gain. The timing of prandial insulin administration may enhance its efficacy/safety and maintain effective weight control.  

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up

Top

Postprandial blood glucose predicts cardiovascular events and all cause mortality in type 2 diabetes in a 14 year follow up Cavalot F, Pagliarino A, Valle M, et al. Diabetes Care. 2011 34(10) 2237 2243. Cavalot and colleagues conducted a 14-year follow-up of the San Luigi Gonzaga Diabetes Study to assess the role of postprandial blood glucose in predicting CV events and all-cause mortality among subjects with type 2 diabetes. This follow-up study included 505 subjects that were enrolled in initial 5-year study.

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes

Top

Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med. 2011;123(4):63-70. The mechanism of action of dipeptidyl peptidase-4 inhibitors, such as saxagliptin, makes them suitable for combination therapy in type 2 diabetes mellitus (T2DM).

Efficacy & Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared w/ Exenatide Twice Daily & Sitagliptin in Type 2 Diabetes Mellitus

Top

Pinelli NR, Hurren KM. Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis (July/August). Ann Pharmacother. 2011 Jul 5. [Epub ahead of print]. Long-acting glucagon-like peptide-1 receptor agonists (LA-GLP-1RAs) may deliver additional therapeutic benefits over other available incretin-based therapies.

Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers

Top

Abbasi F, Lamendola C, Leary ET, Reaven GM. Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers. Diabetes, Obesity and Metabolism. 2009;11(8):779-785. Fasting hypertriglyceridaemia has been reported to occur commonly in cigarette smokers and is thought to increase cardiovascular disease (CVD) risk in these individuals.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes (LEAD-6)

Top

Buse JB, Rosenstock J, Sesti G, et al for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47. Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. We compared the efficacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist.

1 2 3 4 5 6 7 8 Next 

Slide Library Results

Search Results for: Postprandial Slides Found: 43
Acarbose: Effect on Postprandial Glucose
Acute Effect of Peptide YY3-36 on Food Intake
Increased Fructose Consumption and the Rise in Obesity
Effect of Sibutramine, Orlistat, and Metformin on Risk Factors for Type 2 Diabetes
Acarbose: Effect on Postprandial Glucose
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Exenatide: Effect on the Beta-Cell
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
Effects of Exenatide LAR on A1C in Patients With Type 2 Diabetes
Effects of Exenatide LAR on Weight in Patients With Type 2 Diabetes
Pioglitazone Reduces the Risk of Hospitalization for AMI
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
HEART2D Trial: A1C Values at Each Visit for 60 Months
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Improved Glycemic Control When Adding Metformin to Insulin Therapy
Saxagliptin for Treatment of Type 2 Diabetes: Design
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in FPG from Baseline to Week 24
San Luigi Gonzaga Diabetes Study: Design
San Luigi Gonzaga Diabetes Study: Results
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Design
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Study Protocol and Meals
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Results for Glucose and Hormones
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Summary of Findings
ADA Nutrition Guidelines: Carbohydrates
Liraglutide Enhances Glucose-Dependent Insulin Secretion
Emplagliflozin SGLT 2 A1C EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Weight Loss EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Insulin EMPA-REG MDI Study | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 EMPA-REG MDI Study | NDEI
Diabetes Pregnancy Guidelines Endocrine Society Glucose Monitoring | NDEI
A1C Targets Pregnancy ADA Type 1 Diabetes Guidelines | NDEI Slides
ADA EASD Type 2 Diabetes Treatment Hyperglycemia PPT | NDEI
AACE 2015 Diabetes Guidelines Glycemic Target A1C PPT | NDEI
AACE 2015 Diabetes Guidelins Glycemic Targets Pregnancy GDM PPT | NDEI
AACE 2015 Guidelines Treating Gestational Diabetes GDM PPT | NDEI
Glycemic Targets for Adults With Diabetes A1C ADA Guidelines | NDEI
Glycemic Targets for Children With Type 1 Diabetes ADA Guidelines | NDEI